The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2019 | First-in-human bispecific CAR T-cell therapy for R/R non Hodgkin lymphoma
Nirav Niranjan Shah, MD, from the Medical College of Wisconsin, Milwaukee, WI, delivers updates from the first-in-human Phase I dose-escalation study of bispecific anti-CD19, anti-CD20 CAR T-cells (CAR-20.19-T) for relapsed/refractory non-Hodgkin Lymphoma (NCT03019055). Dr Shah was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.
